37.Issue 11 november 23 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 10, Issue : 11, November – 2023

Title:

SKIN DISEASES, OBESITY AND DIABETES

Authors :

Lujain Salah Abusadi

Abstract :

The project was conducted to explore the prevalence of skin diseases among diabetes and/or obesity patients. Only a little attention has been paid to its prevalence. obesity alters the barrier of the skin and induces manifestation. The commonest cutaneous manifestations associated with obesity are acanthosis nigricans, acrochordon, striae distensae, plantar hyperkeratosis, and intertrigo. Obesity also associated with hyperandrogenism in women, which promoting skin diseases like hirsutism, acne or androgenic alopecia. Insulin plays an important role in the physiology of the skin. IR induced in patients with chronic inflammation, lead to cutaneous manifestations like psoriasis. Acanthosis nigricans consider an early skin sign of diabetes mellitus. Poor control of diabetes mellitus increases the capability of skin infections. The commonest skin manifestations in diabetes patients are bacterial and fungal infection, skin tags, xeroderma, and brown spots. Weight loss is an important method for humans to decrease metabolic diseases, increase self-confidence, and improve patient lifestyle. Weight loss interventions are different, liraglutide considered one of these interventions as it’s showing it’s effectively to decrease body weight that leads to improvement or treat skin disease too.

Cite This Article:

Please cite this article in Lujain Salah Abusadiet al, Skin Diseases, Obesity And Diabetes, Indo Am. J. P. Sci, 2023; 10 (11).

Number of Downloads : 10

References:

1. Ozlu, E., Uzuncakmak, T.K., Takır, M., Akdeniz, N. and Karadag, A.S., 2018. Comparison of cutaneous manifestations in diabetic and nondiabetic obese patients: A prospective, controlled study. Northern clinics of Istanbul, 5(2), p.114 [Online]. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191549/ [Accessed 23 September 2020].

2. American Diabetes Association, 2014. Diagnosis and classification of diabetes mellitus. Diabetes care, 37(Supplement 1), pp.S81-S90. [Online]. Available at: https://care.diabetesjournals.org/content/33/supplement_1/s62.short [Accessed 19 September 2020]?

3. Boza, J.C., Trindade, E.N., Peruzzo, J., Sachett, L., Rech, L. and Cestari, T.F., 2012. Skin manifestations of obesity: a comparative study. Journal of the European Academy of Dermatology and Venereology, 26(10), pp.1220-1223. [Online]. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1468-3083.2011.04265.x [ Accessed 20 October 2020].

4. Al-Mutairi, N., 2011. Associated cutaneous diseases in obese adult patients: a prospective study from a skin referral care center. Medical Principles and Practice, 20(3), pp.248-252. [Online]. Available at: https://www.karger.com/Article/Abstract/323597 [Accessed 4 October 2020].

5. Svensson, A., Ofenloch, R.F., Bruze, M., Naldi, L., Cazzaniga, S., Elsner, P., Goncalo, M., Schuttelaar, M.L. and Diepgen, T.L., 2018. Prevalence of skin disease in a population‐based sample of adults from five European countries. British journal of dermatology, 178(5), pp.1111-1118. [Online]. Available at: https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.16248 [Accessed 11 October 2020].

6. Shahzad, M., Al Robaee, A., Al Shobaili, H.A., Alzolibani, A.A., Al Marshood, A.A., and Al Moteri, B., 2011. Skin manifestations in diabetic patients attending a diabetic clinic in the Qassim region, Saudi Arabia. Medical Principles and Practice, 20(2), pp.137-141. [Online]. Available at: https://www.karger.com/Article/Abstract/321219 [Accessed 23 October 2020].

7. Tseng, H.W., Ger, L.P., Liang, C.K., Liou, H.H. and Lam, H.C., 2015. High prevalence of cutaneous manifestations in the elderly with diabetes mellitus: an institution‐based cross‐sectional study in Taiwan. Journal of the European Academy of Dermatology and Venereology, 29(8), pp.1631-1635.[Online]. Available at https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.12664 [Accessed 25 October 2020].

8. Foss, N.T., Polon, D.P., Takada, M.H., Foss-Freitas, M.C. and Foss, M.C., 2005. Skin lesions in diabetic patients. Revista de saude publica, 39, pp.677-682.[Online]. Available at: https://www.scielosp.org/article/rsp/2005.v39n4/677-682/en/ [Accessed 4 November 2020]

9. Ahmed, K., Muhammad, Z. and Qayum, I., 2009. Prevalence of cutaneous manifestations of diabetes mellitus. J Ayub Med Coll Abbottabad, 21(2), pp.76-9. [Online]. Available at http://www.ayubmed.edu.pk/JAMC/PAST/21-2/Khurashid.pdf [Accessed 6 November 2020].

10. Ragunatha, S., Anitha, B., Inamadar, A.C., Palit, A. and Devarmani, S.S., 2011. Cutaneous disorders in 500 diabetic patients attending diabetic clinic. Indian journal of dermatology, 56(2), p.160. [Online]. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108514/ [Accessed: 10 November 2020]

11. Khalil, G.M., Al Shobaili, H.A., Alzolibani, A. and Al Robaee, A., 2011. Relationship between obesity and other risk factors and skin disease among adult Saudi population. The Journal Of The Egyptian Public Health Association, 86(3 and 4), pp.56-62. [Online] . Available at https://journals.lww.com/ephaj/FullText/2011/08000/Relationship_between_obesity_and_other_risk.4.aspx [Accessed 15 Nobody 2020].

12. Niaz, F., Bashir, F., Shams, N., Shaikh, Z. and Ahmed, I., 2016. Cutaneous manifestations of diabetes mellitus type 2: prevalence and association with glycemic control. Journal of Pakistan Association of Dermatology, 26(1), pp.4-11.[Online]. Available at: http://www.jpad.com.pk/index.php/jpad/article/view/67 [Accessed 22 November 2020].

13. Galdeano, F., Zaccaria, S., Parra, V., Giannini, M.E. and Salomón, S., 2010. Cutaneous manifestations of diabetes mellitus: clinical meaning. Dermatología Argentina, 16(2010), pp.117-121. [Online]. Available at https://www.dermatolarg.org.ar/index.php/dermatolarg/article/view/1093 [Accessed 25 November 2020].

14. Napolitano, M., Megna, M. and Monfrecola, G., 2015. Insulin resistance and skin diseases. The Scientific World Journal, 2015. [Online]. Available at https://www.hindawi.com/journals/tswj/2015/479354/ [Accessed 10 December 2020].

15. Makrantonaki, E., Jiang, D., Hossini, A.M., Nikolakis, G., Wlaschek, M., Scharffetter-Kochanek, K. and Zouboulis, C.C., 2016. Diabetes mellitus and the skin. Reviews in Endocrine and Metabolic Disorders, 17(3), pp.269-282. [Online]. Available at: https://link.springer.com/article/10.1007/s11154-016-9373-0 [Accessed: 12 December 2020].

16. Bustan, R.S., Wasim, D., Yderstræde, K.B. and Bygum, A., 2017. Specific skin signs as a cutaneous marker of diabetes mellitus and the prediabetic state-a systematic review. Dan Med J, 64(1), p.A5316. [Online]. Available at: https://findresearcher.sdu.dk:8443/ws/files/125492531/Specific_skin_signs_as_a_cutaneous_marker_of_diabetes_mellitus_and_the_prediabetic_state.pdf [Accessed: 15 December 2020].

17. Hirt, P.A., Castillo, D.E., Yosipovitch, G. and Keri, J.E., 2019. Skin changes in the obese patient. Journal of the American Academy of Dermatology, 81(5), pp.1037-1057.[Online]. Available at: https://www.sciencedirect.com/science/article/pii/S0190962219301586 [Accessed: 16 December 2020].

18. Yosipovitch, G., DeVore, A. and Dawn, A., 2007. Obesity and the skin: skin physiology and skin manifestations of obesity. Journal of the American Academy of Dermatology, 56(6), pp.901-916. [Online]. Available at: https://www.sciencedirect.com/science/article/pii/S0190962206041053 [Accessed: 18 December 2020].

19. Rosen, J., Darwin, E., Tuchayi, S.M., Garibyan, L. and Yosipovitch, G., 2019. Skin changes and manifestations associated with the treatment of obesity. Journal of the American Academy of Dermatology, 81(5), pp.1059-1069. [Online]. Available at : https://www.sciencedirect.com/science/article/pii/S0190962219301598 [Accessed: 17 December 2020].

20. Mancini, M.C. and de Melo, M.E., 2017. The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. Diabetology & metabolic syndrome, 9(1), p.44. [Online]. Available at: https://link.springer.com/article/10.1186/s13098-017-0242-0 [Accessed: 18 December 2020].

21. Davies, M.J., Bergenstal, R., Bode, B., Kushner, R.F., Lewin, A., Skjøth, T.V., Andreasen, A.H., Jensen, C.B. and DeFronzo, R.A., 2015. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. Jama, 314(7), pp.687-699. [Online]. Available at: https://jamanetwork.com/journals/jama/article-abstract/2428956 [Accessed: 17 December 2020].

22. Xu, X., Lin, L., Chen, P., Yu, Y., Chen, S., Chen, X. and Shao, Z., 2019. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes research and clinical practice, 150, pp.167-173. [Online]. Available at: https://www.sciencedirect.com/science/article/pii/S0168822718319296 [Accessed: 19 December 2020].

23. Lin, L., Xu, X., Yu, Y., Ye, H., He, X., Chen, S., Chen, X., Shao, Z. and Chen, P., 2020. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. Journal of Dermatological Treatment, pp.1-7. [Online]. Available at : https://www.tandfonline.com/doi/abs/10.1080/09546634.2020.1826392 [Accessed: 20 December 2020].

24. Khandalavala, B.N., 2017. A disease-modifying approach for advanced hidradenitis suppurativa (regimen with metformin, liraglutide, dapsone, and finasteride): a case report. Case reports in dermatology, 9(2), pp.70-78. [Online]. Available at: https://www.karger.com/Article/Abstract/473873 [Accessed: 18 December 2020].

25. Christou, G.A., Katsiki, N., Blundell, J., Fruhbeck, G., and Kiortsis, D.N., 2019. Semaglutide as a promising antiobesity drug. Obesity Reviews, 20(6), pp.805-815. [Online]. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1111/obr.12839 [Accessed: 22 December 2020].

26. O’Neil, P.M., Birkenfeld, A.L., McGowan, B., Mosenzon, O., Pedersen, S.D., Wharton, S., Carson, C.G., Jepsen, C.H., Kabisch, M. and Wilding, J.P., 2018. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet, 392(10148), pp.637-649. [Online]. Available at: https://www.sciencedirect.com/science/article/pii/S0140673618317732 [Accessed: 24 December 2020].